SKYTROFA® has been studied in treatment-naïve and ‑experienced children with GHD, totaling more than 300 patients1-3
SKYTROFA PHASE 3 PROGRAM IN PEDIATRIC GHD1‑4
*Patients aged < 3 years could be treatment naïve and were included only in the safety and tolerability analyses.3
A total of 298 of the 303 children with GHD who had completed the heiGHt and fliGHt trials continued into the enliGHten open-label extension for long-term safety assessments1-4
Review phase 3 efficacy and safety data for pediatric patients taking SKYTROFA